NCT05013502View on ClinicalTrials.gov

Empagliflozin in Diuretic Refractory Ascites

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

June 30, 2023

Conditions
Liver CirrhosisCirrhosisAscitesAscites HepaticSodium-Glucose Transporter 2 Inhibitors
Interventions
DRUG

Empagliflozin 10 MG

empagliflozin 10mg PO once daily

Trial Locations (1)

94060

Stanford University Digestive Health Clinic, Redwood City

All Listed Sponsors
lead

Stanford University

OTHER

NCT05013502 - Empagliflozin in Diuretic Refractory Ascites | Biotech Hunter | Biotech Hunter